Type | Public | |
Founded | 1989 | |
HQ | Boston, MA, US | Map |
Website | vrtx.com | |
Employee Ratings | More | |
Overall Culture | A+ | More |
USD | |
---|---|
Revenue (FY, 2020) | 6.2b |
Gross profit (FY, 2020) | 5.5b |
Gross profit margin (FY, 2020), % | 88.1% |
Net income (FY, 2020) | 2.7b |
EBIT (FY, 2020) | 2.9b |
Market capitalization (1-Mar-2021) | 54.7b |
Closing stock price (1-Mar-2021) | 210.4 |
Cash (31-Dec-2020) | 6.0b |
EV | 49.6b |
USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 143.4m | 1.4b | 1.5b | 1.2b | 580.4m | 1.0b | 1.7b | 2.5b | 3.0b | 4.2b | 6.2b |
Revenue growth, % | (52%) | 78% | 65% | ||||||||
Cost of goods sold | 63.6m | 236.7m | 89.0m | 39.7m | 117.2m | 206.8m | 272.7m | 409.5m | 547.8m | 736.3m | |
Gross profit | 1.3b | 1.3b | 1.1b | 540.7m | 915.2m | 1.5b | 2.2b | 2.6b | 3.6b | 5.5b |
USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 22.4m | 31.6m | 23.8m | 73.7m | 114.4m | 659.2m | 438.7m | 418.3m | 336.0m | 328.4m | 310.8m | 221.7m | 118.5m | 138.4m | 179.0m | 138.5m | 166.1m | 309.8m | 398.1m | 431.6m | 413.8m | 714.7m | 544.1m | 578.2m | 640.8m | 752.2m | 784.5m | 858.4m | 941.3m | 949.8m | 1.5b | 1.5b | 1.5b |
Cost of goods sold | 5.4m | 35.3m | 25.9m | 104.5m | 30.7m | 31.0m | 24.7m | 20.0m | 8.6m | 9.7m | 10.2m | 9.4m | 15.4m | 30.3m | 49.8m | 44.2m | 53.2m | 46.2m | 70.5m | 72.2m | 71.6m | 104.4m | 111.3m | 95.1m | 135.7m | 131.9m | 162.5m | ||||||
Gross profit | 109.0m | 623.9m | 412.8m | 313.8m | 305.3m | 297.4m | 286.1m | 201.7m | 109.9m | 128.8m | 168.8m | 129.1m | 150.7m | 279.5m | 348.3m | 387.5m | 360.6m | 668.5m | 473.6m | 506.0m | 569.2m | 647.8m | 673.3m | 763.3m | 805.6m | 817.9m | 1.4b | ||||||
Gross profit Margin, % | 95% | 95% | 94% | 75% | 91% | 91% | 92% | 91% | 93% | 93% | 94% | 93% | 91% | 90% | 87% | 90% | 87% | 94% | 87% | 88% | 89% | 86% | 86% | 89% | 86% | 86% | 89% |
USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 243.2m | 475.3m | 489.4m | 569.3m | 625.3m | 714.8m | 1.2b | 1.7b | 2.7b | 3.1b | 6.0b |
Accounts Receivable | 12.5m | 183.1m | 143.3m | 85.5m | 76.0m | 177.6m | 201.1m | 281.3m | 409.7m | 633.5m | 885.4m |
Prepaid Expenses | 14.9m | 24.7m | 23.8m | 52.6m | 50.9m | 165.6m | 140.8m | 213.5m | 308.4m | ||
Inventories | 112.4m | 30.5m | 14.1m | 30.8m | 57.2m | 77.6m | 111.8m | 124.4m | 167.5m | 280.8m |
USD | Q1, 2010 | Q2, 2010 | Q3, 2010 | Q1, 2011 | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 396.5m | 337.6m | 569.9m | 446.5m | 458.2m | 542.5m | 267.9m | 454.1m | 436.9m | 379.1m | 531.2m | 583.2m | 424.0m | 420.6m | 718.6m | 664.9m | 870.5m | 756.3m | 604.2m | 605.9m | 719.7m | 1.0b | 1.2b | 1.4b | 2.0b | 2.1b | 2.5b | 2.9b | 3.3b | 3.4b | 3.6b | 4.8b | 5.4b |
Accounts Receivable | 7.9m | 3.5m | 5.0m | 5.6m | 96.0m | 445.7m | 232.2m | 185.6m | 139.6m | 194.1m | 164.9m | 120.3m | 59.9m | 81.8m | 114.3m | 80.3m | 94.5m | 165.3m | 181.9m | 189.4m | 182.2m | 208.0m | 247.9m | 263.5m | 327.3m | 393.4m | 379.8m | 438.3m | 464.9m | 443.3m | 845.3m | 791.8m | 791.9m |
Prepaid Expenses | 23.2m | 35.4m | 40.5m | 35.1m | 47.8m | 43.2m | 41.1m | 35.0m | 34.4m | 41.3m | 62.6m | 53.3m | 63.4m | 55.9m | 56.3m | 61.0m | 128.5m | 107.1m | 152.2m | 109.9m | 122.7m | 118.7m | 130.0m | 151.8m | 175.1m | 223.6m | 232.6m | 270.0m | |||||
Inventories | 17.8m | 52.6m | 67.7m | 129.6m | 87.8m | 86.3m | 21.5m | 19.5m | 13.5m | 11.3m | 12.0m | 16.8m | 34.1m | 42.1m | 49.2m | 63.2m | 66.6m | 71.8m | 82.0m | 92.3m | 98.2m | 117.3m | 115.0m | 124.2m | 136.7m | 143.0m | 162.3m | 187.1m | 219.2m | 245.5m |
USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (754.6m) | 29.6m | (107.0m) | (687.5m) | (742.7m) | (588.2m) | (84.0m) | 91.6m | 2.1b | 1.2b | 2.7b |
Depreciation and Amortization | 30.5m | 35.0m | 38.2m | 48.4m | 63.3m | 62.3m | 61.4m | 61.4m | 72.4m | 106.9m | 109.5m |
Inventories | (111.4m) | (29.9m) | 7.1m | (16.5m) | (23.1m) | (16.4m) | (45.0m) | (32.0m) | (64.0m) | (132.0m) | |
Accounts Payable | (1.2m) | 37.5m | 14.9m | (49.2m) | 25.0m | (1.7m) | (11.7m) | 8.8m | 36.6m | (22.8m) | 51.3m |
USD | Q1, 2010 |
---|---|
Financial Leverage | 1.8 x |
Company Name | Date | Deal Size |
---|---|---|
Semma Therapeutics | September 03, 2019 | $950 m |
Vertex Pharmaceuticals has 65.77k Twitter Followers. The number of followers has increased 0.7% month over month and increased 1.2% quarter over quarter
2.9k
Tweets
88
Following
65.8k
Followers
10
Tweets last 30 days
18.7
Avg. likes per Tweet
100%
Tweets with engagement
A+
92/100
A+
85/100
A+
95/100
A+
91/100
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989.
Who are Vertex Pharmaceuticals key executives?
Vertex Pharmaceuticals's key executives are Jeffrey Leiden, Reshma Kewalramani and Sangeeta N. Bhatia.
How many employees does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 3,000 employees.
What is Vertex Pharmaceuticals revenue?
Latest Vertex Pharmaceuticals annual revenue is $6.2 b.
What is Vertex Pharmaceuticals revenue per employee?
Latest Vertex Pharmaceuticals revenue per employee is $2.1 m.
Who are Vertex Pharmaceuticals competitors?
Competitors of Vertex Pharmaceuticals include Amphastar Pharmaceuticals, Biogen and Otonomy.
Where is Vertex Pharmaceuticals headquarters?
Vertex Pharmaceuticals headquarters is located at 50 Northern Ave, Boston.
Where are Vertex Pharmaceuticals offices?
Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations.
How many offices does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 27 offices.
Receive alerts for 300+ data fields across thousands of companies